The Virtus Management Team is experienced, nimble and focused on creating value and generating results.
Vinod Melvani is the CEO at Virtus Pharmaceuticals LLC and is responsible for providing strategic direction, management oversight and overall business execution. Vinod joined the Virtus BOD in April 2017 and assumed the CEO role in April 2019. His prior experiences include three years as President, Pharma Channel Consulting, and over fifteen years at McKesson Corp. where he held several key roles including SVP/Head of the US Generics business. Prior to McKesson, he spent 8 years in healthcare management consulting.
Vinod is a results-driven pharmaceutical executive with over 25 years in the healthcare industry. He brings a strong blend of strategic thinking and hands-on operating experience within the pharmaceutical supply chain.
Vinod holds an MBA from Case Western Reserve University and a Bachelor's degree in Commerce from Mumbai University.
Kathleen Farley joined Virtus Pharmaceuticals in May 2019 and is the Chief Operating Officer. Kathleen is responsible for Supply Chain, Operations and Quality Assurance. Previously, Kathleen held positions with Merck as the VP Franchise Head of Operations and with Teva as the VP Head of US Operations. She has additional experience and expertise in start-ups/shutdowns of operations in Asia Pacific and Latin America. Kathleen is currently a Manufacturing Advisory Board Member for Gilead Sciences.
Kathleen has extensive global leadership experience in Pharmaceutical, Chemical, Biotech, Medical Device and OTC technical operations, manufacturing and supply chain. She has a proven track record of success in managing a broad range of multi-million-dollar operations in both Branded and Generic Pharmaceuticals and transforming Clinical/Development start-ups to Commercial manufacturing operations.
Kathleen holds an MBA from Fordham University and a Bachelor's Degree in Chemical Engineering/Biomedical Engineering from Michigan State University.
Barry Lederman joined Virtus in May 2019 as Chief Financial Officer. In this capacity, he is responsible for Accounts Receivable, Accounts Payable, Accounting, Financial Planning & Analysis, Government Pricing & Reporting, Tax and Information Technology.
Barry has extensive financial and international pharmaceutical experience, having led teams of several public and private companies with global operations including a recent sale of Halo Pharmaceuticals (private equity ownership) to Cambrex Corporation (USA publicly held) for $425MM in September 2018. Prior to joining Halo, he served as the Vice President and CFO for Eisai Inc. with operations in the Americas Region, the CFO at Wedgewood Pharmacy, Nycomed US Inc., and Qualitrol Company LLC (a subsidiary of Danaher Corporation).
Barry also spent 10 years with Roche in positions of increasing responsibility within Finance, culminating in his appointment as Senior Vice President – Head of Business Analysis and Controller at Roche Centralized Diagnostics, headquartered in Mannheim, Germany.
Barry holds a Master of Business Administration with a dual concentration in Finance and Operations Management from the University of Rochester – Simon Business School and a Bachelor of Science degree in Electrical Engineering from the University of Rochester. In addition, he is a certified public accountant licensed in New Jersey and New York and gained his accounting experience at PwC. He also serves as a board member with the Northern New Jersey Council of the Boy Scouts of America
Vishal Gupta, PhD joined Virtus in September 2018 and is the Chief Scientific Officer and Senior Vice President, BD&L. In this capacity, he is responsible for R&D including Biopharmaceutics, Regulatory Affairs, Pharmacovigilance, Project Management, New Product Launch, and Technical Services, Business Development & Licensing and Portfolio Management.
Vishal has extensive industry experience in NDA, 505(b)(2) and ANDA space in R&D and Business Development. Most recently as SVP, US R&D at Alvogen, where he was responsible for R&D, Biopharmaceutics, Clinical Development, Clinical Operations, Project Management Office, New Product Launch, and Technical Services at all internal and external manufacturing sites. Prior to that, he was Chief Scientific Officer and SVP, Global R&D at Impax Labs, and Chief Scientific Officer and SVP, Generics and Brand R&D at CorePharma. He also served in positions of increasing responsibility at Mallinckrodt, Pfizer, and Sun Pharma.
Vishal holds a PhD in Pharmaceutics from The University of Georgia, Athens, GA, an MBA in Strategy and Finance from Washington University, St. Louis, MO, an MS in Pharmaceutics from IIT, Banaras Hindu University, India, and a BS in Pharmacy from Amravati University, India. Vishal is a certified Six Sigma Black Belt and a former Officer of the American Association of Pharmaceutical Scientists. He served as Adjunct Assistant Professor at Midwestern College of Pharmacy, Chicago, IL and St. Louis College of Pharmacy, St. Louis, MO. Vishal is an inventor/co-inventor of several patents, has published peer-reviewed research articles, and has given numerous invited presentations around the world.
Warren Pefley joined Virtus in January 2016 and is the Sr. Vice President of Sales and Marketing. Warren is responsible for the Sales Team, Customer Service, Marketing and Product Management, Contracts and Pricing, Demand Planning and Customer Forecast. Previously, Warren held positions with Bristol-Myers Squibb, Sandoz and Qualitest (now Par Pharmaceuticals).
Warren has extensive experience in the pharmaceutical industry having held positions in Sales, Sales Management, Product Strategy and Customer Marketing, gaining expertise with oral dose and hospital injectable products across the continuum of customers in the U.S.
Warren holds a Bachelor's Degree in Business Administration from Grand Valley State University.
Timothy Wheeler joined Virtus in January 2018 and is the Vice President of Quality Assurance. Tim is responsible for all quality assurance and compliance activities for the company and its contract partners. Previously, Tim was the Senior Director of Quality Operations at West-Ward Pharmaceuticals Corporation (now Hikma) in Cherry Hill, NJ.
Tim has extensive experience in domestic and international quality assurance and regulatory affairs including long-term expatriate assignments.
Tim holds a Bachelor's Degree in Chemistry from the University of Connecticut.
John Peck joined Virtus in April 2018 and is the Executive Director, Business Development and Portfolio, where John directs the company's Business Development activity and established the New Products screening process. John directed the Portfolio team resulting in the identification of 11 new pipeline products, encompassing injectables, ophthalmics, topicals, oral solutions and controlled-substance oral solids.
John led due diligence teams to acquire a C-II oral solid product in a single-player market, resulting in over $30M first year sales. He identified and managed market research for the launch of a specialty ophthalmic product with no generic competitors. John further identified a specialty injectables product line and teamed with manufacturing partners to position Virtus as the first generic entrant within the hospital and clinical space. John's prior experience has been with Hikma Plc, Actavis, Bristol-Myers Squibb, Celgene and Schweizerhall, SA in positions of increasing responsibility encompassing strategic sourcing, marketing, business development, and M&A.
John has executed more than 50 pharmaceutical product acquisitions and licenses and has been elected to and served as Executive Officer and Board of Directors of DCAT.
John holds a Bachelors of Science Degree in Chemistry and Chemical Engineering from Kansas State University